From: Eczema as a protective factor for brain cancer: a meta-analysis
Study, year | Study design | Region | Cancer | Sample size | Cases | Controls | Age range | Date range | NOS score |
---|---|---|---|---|---|---|---|---|---|
Ryan, 1992 [16] | Case-control | Australia | Glioma | 527 | 110 | 417 | 25–74 | 1987.02–1990.03 | 7 |
Cicuttini, 1997 [17] | Case-control | Australia | Glioma | 838 | 416 | 422 | 20–70 | 1987.7–1992.10 | 8 |
Schlehofer, 1999(M) [18] | Case-control | Other | Meningioma | 1454 | 331 | 1123 | 20–80 | 1980–1991 | 6 |
Schlehofer, 1999(G) [18] | Case-control | Other | Glioma | 3165 | 1178 | 1987 | 20–80 | 1980–1991 | 6 |
Brenner, 2002 [19] | Case-control | America | CNS tumors | 1288 | 489 | 799 | 18–90 | 1994.6–1988.8 | 7 |
Schwartzbaum, 2003(G) [20] | Cohort | Europe | Glioma | 14,535 | NA | NA | 42–81 | NA | 9 |
Schwartzbaum, 2003(M) [20] | Cohort | Europe | Meningioma | 14,535 | NA | NA | 42–81 | NA | 9 |
Schwartzbaum, 2005 [21] | Case-control | Europe | Glioma | 806 | 173 | 633 | 43–62 | NA | 8 |
Schoemaker, 2006 [22] | Case-control | Europe | Glioma | 2681 | 965 | 1716 | 18–59 | 2000–2004 | 8 |
Schoemaker, 2007 [23] | Case-control | Europe | Meningioma | 2191 | 475 | 1716 | 18–69 | 2001–2004 | 7 |
Wigertz, 2007 [24] | Case-control | Europe | CNS tumors | 4836 | 1527 | 3309 | ≥18 | 2000.9–2004.2 | 8 |
Harding, 2008 [25] | Case-control | Europe | CNS tumors | 6867 | 575 | 6292 | 2–15 | 1991–1996 | 8 |
Berg-Beckhoff, 2009(G) [26] | Case-control | Europe | Glioma | 1098 | 366 | 732 | 30–69 | 2000.11–2003.11 | 8 |
Berg-Beckhoff, 2009(M) [26] | Case-control | Europe | Meningioma | 1143 | 381 | 762 | 30–69 | 2000.11–2003.11 | 8 |
Il’yasova, 2009 [27] | Case-control | America | Glioma | 565 | 388 | 177 | ≥18 | 2003.8–2008.4 | 7 |
Schoemaker, 2009 [28] | Case-control | Europe | Pituitary tumor | 929 | 299 | 630 | 18–59 | 2000.12–2005.2 | 8 |
Roncarolo, 2012 [29] | Case-control | America | CNS tumors | 16 | 6 | 10 | 0–14 | 1980–1999 | 9 |
Turner, 2013 [30] | Case-control | Other | Acoustic neuroma | 199 | 34 | 165 | 30–59 | 2000-–004 | 8 |
Amirian, 2016 [31] | Case-control | Other | Glioma | 8019 | 4270 | 3749 | 18–80 | NA | 7 |
Lupatsch, 2018 [32] | Case-control | Europe | CNS tumors | 3188 | 469 | 2719 | 1–14 | NA | 8 |
Pouchieu, 2018(G) [33] | Case-control | Europe | Glioma | 777 | 253 | 524 | ≥16 | 2004–2010 | 8 |
Pouchieu, 2018(M) [33] | Case-control | Europe | Meningioma | 627 | 206 | 421 | ≥16 | 2004–2010 | 8 |
D’Arcy, 2019 [34] | Case-control | America | CNS tumors | 1,844,575 | 15,205 | 100,000 | 66–99 | 1992–2013 | 7 |
Mansfield, 2020(U) [35] | Cohort | Europe | CNS tumors | 2,711,745 | NA | NA | 24.9–60.7 | 1998.2–2016.3 | 8 |
Mansfield, 2020(D) [35] | Cohort | Europe | CNS tumors | 490,618 | NA | NA | 1.7–21.1 | 1982.2–2016.6 | 8 |